Skip to content

To Study the Effect of Asana Malahara in Ahiputana ( Napkin Dermatitis ) in Infants

Evaluation of the efficacy of Asana Malahara in Ahiputana (Napkin Dermatitis) in Infants - NIL

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/05/087751
Enrollment
55
Registered
2025-05-28
Start date
Unknown
Completion date
Unknown
Last updated
2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L22- Diaper dermatitis

Interventions

Intervention1: Medicine : Asana Malahara: Reference: Ashtang Hriday Uttarsthan Adhyay 2 Shlok 74 Route: External Application Dosage Form : Sufficient amount depending upon area Frequency: tds Duratio

Sponsors

Dr Ganesh Babruwan Patil
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Infants who suffers with Ahiputana 2.Infants age upto 1 year. 3.Patients will be selected irrespective of sex and socioeconomic status. 4.The patients whose parents are ready to participate in the clinical trial by giving informed written consent.

Exclusion criteria

Exclusion criteria: 1.Infants having other generalized skin infections. 2.Infants having life threatening illness. 3.Infants who are known cases of systemic illness. 4.Infants who have other than clinical signs and symptoms of AHIPUTANA. 5.Children Above 1 Year of age. 6.History of Ahiputana more than 10 days.

Design outcomes

Primary

MeasureTime frame
We will see the effect of interventional drug on the skin rash and itching Of AHIPUTANA Are Expected To Be Reduced After The Use Of Asana Malahara In Infants Timepoint: We will see the effect of interventional drug on the skin rash and itching Of AHIPUTANA Are Expected To Be Reduced After The Use Of Asana Malahara In Infants

Secondary

MeasureTime frame
The Symptoms Like Kandu And Pidika Are Expected To Be Relieved Maximum And Other Symptoms Had Moderate Relief And Also There Will Be Minimum Adverse Effects Timepoint: 5 days study with follow up on 3rd and 5th day (0,3,5 days)

Countries

India

Contacts

Public ContactDr Ganesh Babruwan Patil

Dr. D. Y. Patil College of Ayurved and Research Centre

dr.mosim2010@gmail.com7350751503

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Sep 19, 2026